SEC Form 4Coverage since Aug 3, 2026
$MBRX insider trading
Over the last 12 months, Moleculin Biotech insiders reported 3 buys totaling — and no sales across SEC Form 4 filings.
- Bought · 12m
- — 3 events
- Sold · 12m
- — 0 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $MBRX · 12Mvia TradingView
Top insiders · 12m
Foster Jonathan P.Chief Financial Officer1× · —
KLEMP WALTER VCEO and President1× · —
PICKER DONALD HChief Science Officer1× · —
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Foster Jonathan P.Chief Financial Officer · O | ▲ Buy | 293,333 | — | — | +2377.1% | — |
| Aug 3, 2026 | KLEMP WALTER VCEO and President · O·D | ▲ Buy | 533,333 | — | — | +1720% | — |
| Aug 3, 2026 | PICKER DONALD HChief Science Officer · O | ▲ Buy | 173,333 | — | — | +23019% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MBRX feed.